Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
We hope to serve our community with infusions to help this unmet medical need while continuing to work on the next generation of Alzheimer treatments.
Medicare should require safety monitoring and medical expertise in the use of aducanumab.